CytomX Therapeutics (CTMX) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Indaptus Therapeutics (INDP) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 52.4% versus a loss of 47.7%. Over five years, CTMX leads with a -69.9% price change compared with -98.3% for INDP. CytomX Therapeutics is the larger company by market cap ($442.5 million vs $433.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | INDP |
|---|---|---|
| Share price | $2.03 | $2.82 |
| Market cap | $442.55M | $433.16M |
| 1-day change | -0.98% | -9.90% |
| YTD return | -52.35% | -3.09% |
| 1-year return | -47.68% | +52.43% |
| 5-year return | -69.93% | -98.26% |
| EPS (TTM) | $-0.51 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $76.20M | — |
| Revenue growth (YoY) | -44.82% | — |
| Net income (latest FY) | $-17.37M | $-20.85M |
| Operating margin | -29.35% | — |
| Net margin | -22.79% | — |
| 52-week high | $8.21 | $5.96 |
| 52-week low | $1.87 | $0.92 |
| Distance from 52-week high | -75.27% | -52.68% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +509.85% | — |
| Average volume | 4.27M | 712.87K |
| Shares outstanding | 218.00M | 153.60M |
| Employees | 69 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDP has outperformed CTMX by 100.1 percentage points over the past year.
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CTMX vs INDP FAQ
Which is bigger, CytomX Therapeutics or Indaptus Therapeutics?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $442.55M compared with $433.16M for Indaptus Therapeutics (INDP).
Which stock has performed better over the past year, CTMX or INDP?
INDP returned +52.43% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.